499 related articles for article (PubMed ID: 32003247)
21. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
Vangipuram R; Tyring SK
Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
[TBL] [Abstract][Full Text] [Related]
22. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
Czarnowicki T; Gonzalez J; Shemer A; Malajian D; Xu H; Zheng X; Khattri S; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2015 Jul; 136(1):104-115.e7. PubMed ID: 25748064
[TBL] [Abstract][Full Text] [Related]
23. A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults.
Pezzolo E; Sechi A; Tartaglia J; Naldi L
Expert Rev Clin Immunol; 2024 Mar; 20(3):255-266. PubMed ID: 37955186
[TBL] [Abstract][Full Text] [Related]
24. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis.
Uppal SK; Kearns DG; Chat VS; Han G; Wu JJ
J Dermatolog Treat; 2022 Mar; 33(2):626-636. PubMed ID: 32507066
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
D'Erme AM; Romanelli M; Chiricozzi A
Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
[TBL] [Abstract][Full Text] [Related]
26. Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges.
Kim HO
Arch Pharm Res; 2022 Dec; 45(12):894-908. PubMed ID: 36462097
[TBL] [Abstract][Full Text] [Related]
27. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Guttman-Yassky E; Krueger JG
Curr Opin Immunol; 2017 Oct; 48():68-73. PubMed ID: 28869867
[TBL] [Abstract][Full Text] [Related]
28. Biological medication in atopic dermatitis.
Fölster-Holst R; Torrelo A; Das K; Murrell DF; Patil A; Rahmat Pour Rokni G; Grabbe S; Staubach P; Sohn A; Goldust M
Expert Opin Biol Ther; 2022 May; 22(5):643-649. PubMed ID: 34991429
[TBL] [Abstract][Full Text] [Related]
29. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients.
Ahn J; Grinich EE; Choi Y; Guttman-Yassky E; Simpson EL
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1449-1460. PubMed ID: 33838838
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
[TBL] [Abstract][Full Text] [Related]
31. Relative efficacy of systemic treatments for atopic dermatitis.
Seger EW; Wechter T; Strowd L; Feldman SR
J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
[TBL] [Abstract][Full Text] [Related]
32. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
Yang N; Chen Z; Zhang X; Shi Y
BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
[TBL] [Abstract][Full Text] [Related]
33. English version of Japanese guidance for biologics in treating atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Oct; 50(10):e311-e322. PubMed ID: 37650357
[TBL] [Abstract][Full Text] [Related]
34. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
Silverberg JI; Kantor R
Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
[TBL] [Abstract][Full Text] [Related]
35. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.
Facheris P; Jeffery J; Del Duca E; Guttman-Yassky E
Cell Mol Immunol; 2023 May; 20(5):448-474. PubMed ID: 36928371
[TBL] [Abstract][Full Text] [Related]
36. An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.
Picone V; Vallone Y; Patruno C; Napolitano M
Expert Rev Clin Pharmacol; 2023; 16(12):1239-1248. PubMed ID: 38054328
[TBL] [Abstract][Full Text] [Related]
37. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
[TBL] [Abstract][Full Text] [Related]
38. Novel therapies in the treatment of atopic dermatitis.
Zhong CS; Elmariah SB
Semin Cutan Med Surg; 2018 Sep; 37(3):190-197. PubMed ID: 30215637
[TBL] [Abstract][Full Text] [Related]
39. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
40. Diversity of atopic dermatitis and selection of immune targets.
Rothenberg-Lausell C; Bar J; Del Duca E; Guttman-Yassky E
Ann Allergy Asthma Immunol; 2024 Feb; 132(2):177-186. PubMed ID: 38008215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
